Elite in Chronic B-Cell Leukemia (CBCL)

Petra Langerbeins

Koeln, NW, DE 
Elite in Chronic B-Cell Leukemia (CBCL)
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Petra Langerbeins practices in Koeln, Germany. Ms. Langerbeins is rated as an Elite expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Leukemia.

Her clinical research consists of co-authoring 48 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 43 articles and participated in 1 clinical trial in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Female

Locations

Koeln, NW, Germany
Other Locations
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib Vs. Placebo in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia Patients with Risk of Early Disease Progression
A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib Vs. Placebo in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia Patients with Risk of Early Disease Progression
Enrollment Status: Completed
Publish Date: December 30, 2024
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 3

48 Total Publications

Efficacy of MRD-triggered Anti-CD20 Retreatment in Patients with High-Risk Chronic Lymphocytic Leukemia: A Case Series.
Efficacy of MRD-triggered Anti-CD20 Retreatment in Patients with High-Risk Chronic Lymphocytic Leukemia: A Case Series.
Journal: Blood advances
Published: May 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Langerbeins's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile